 |
|
Shrinkage of prostate led to overestimation of cancer risk in trial
September 13, 2007Reanalysis of data from the first long-term randomized trial of a chemopreventive agent for prostate cancer shows that the excess prevalence of high-grade prostate cancer in the drug-treated group may be attributable to shrinkage of the prostate at the time of biopsy.
The study of the Prostate Cancer Prevention Trial, led by University of Illinois at Chicago professor of pathology Dr. Peter Gann, is published in the Sept. 12 issue of the Journal of the National Cancer Institute.
The Prostate Cancer Prevention Trial evaluated the drug finasteride, which blocks production of a male hormone within the prostate and is proven effective in treating benign prostatic hyperplasia, or enlargement of the prostate. The trial was stopped in 2003 when finasteride was found to reduce the risk of prostate cancer by nearly 25 percent. However, men assigned to the finasteride group had a greater prevalence of high-grade cancer.
Gann said the results were confusing for clinicians and patients because the drug appeared to retard the development of prostate cancer and decrease its prevalence, but the increased risk of high-grade cancer was unexplained and worrisome.
Researchers reasoned one possible explanation was that because finasteride shrinks the prostate gland, it increases the likelihood that a biopsy will detect high-grade cancer.
"It's logical that if you shrink the size of the gland and then stick needles in it, you're more likely to find cancer if it exists," Gann said.
A second possible source of bias in the trial that may have contributed to overestimation of prostate cancer risk in the finasteride group is that the drug lowers the blood level of prostate-specific antigen by approximately 50 percent. The PSA level is a biological marker doctors use to detect disease, so PSA levels measured in men taking finasteride are routinely adjusted upward. This calculation may have led to overestimation of baseline PSA levels among men in the finasteride group who were already harboring high-grade tumors at the start of the study.
"This is a very unusual situation -- though it will become more common in the future -- where the drug affects the marker we use to find the cancer," said Gann.
Using data from the Prostate Cancer Prevention Trial study, Gann and colleagues developed statistical models that took into account the size of the prostate gland and the number of needle cores that were taken during biopsy. In essence, the researchers compared finasteride to placebo among men with an equivalent number of needle samples per unit of gland volume.
The analyses showed that adjusting for changes in gland size due to the drug could account for all of the excess high-grade tumors.
"Once we did this adjustment, all the excess high-grade went away, and the effect of the drug on low-grade cancer was even stronger, as we would expect," Gann said.
"This drug may have been much better than people thought," Gann said, "and the fears about its impact on high grade tumors may have been exaggerated based on this bias alone."
However, he said, the findings must be interpreted cautiously, and the new results alone do not justify definitive changes in clinical practice or widespread use of the drug.
"Our goal is to improve scientific understanding of what happened in this very important and expensive trial."
University of Illinois at Chicago
Gann said the results were confusing for clinicians and patients because the drug appeared to retard the development of prostate cancer and decrease its prevalence, but the increased risk of high-grade cancer was unexplained and worrisome.
Researchers reasoned one possible explanation was that because finasteride shrinks the prostate gland, it increases the likelihood that a biopsy will detect high-grade cancer.
"It's logical that if you shrink the size of the gland and then stick needles in it, you're more likely to find cancer if it exists," Gann said.
A second possible source of bias in the trial that may have contributed to overestimation of prostate cancer risk in the finasteride group is that the drug lowers the blood level of prostate-specific antigen by approximately 50 percent. The PSA level is a biological marker doctors use to detect disease, so PSA levels measured in men taking finasteride are routinely adjusted upward. This calculation may have led to overestimation of baseline PSA levels among men in the finasteride group who were already harboring high-grade tumors at the start of the study.
"This is a very unusual situation -- though it will become more common in the future -- where the drug affects the marker we use to find the cancer," said Gann.
Using data from the Prostate Cancer Prevention Trial study, Gann and colleagues developed statistical models that took into account the size of the prostate gland and the number of needle cores that were taken during biopsy. In essence, the researchers compared finasteride to placebo among men with an equivalent number of needle samples per unit of gland volume.
The analyses showed that adjusting for changes in gland size due to the drug could account for all of the excess high-grade tumors.
"Once we did this adjustment, all the excess high-grade went away, and the effect of the drug on low-grade cancer was even stronger, as we would expect," Gann said.
"This drug may have been much better than people thought," Gann said, "and the fears about its impact on high grade tumors may have been exaggerated based on this bias alone."
However, he said, the findings must be interpreted cautiously, and the new results alone do not justify definitive changes in clinical practice or widespread use of the drug.
"Our goal is to improve scientific understanding of what happened in this very important and expensive trial."
University of Illinois at Chicago
Prostate Cancer Current Events and Prostate Cancer News RSSRelationship between prostate information and lower urinary-tract symptoms evident
In the December issue of European Urology (http://www.elsevier.com/locate/eururo) Dr. Curtis Nickel and associates report on the evidence of a relationship between prostate inflammation and lower urinary tract symptoms (LUTS) in men enrolled in the REDUCE trial.
A card-swipe for medical tests
University of Utah scientists successfully created a sensitive prototype device that could test for dozens or even hundreds of diseases simultaneously by acting like a credit card-swipe machine to scan a card loaded with microscopic blood, saliva or urine samples.
Media coverage of lung cancer is increasing, and increasingly negative, new report shows
CancerCare today announced that despite an overall increase in news reporting on lung cancer, the overall tone of lung cancer media coverage has become significantly more negative.
Supercomputer provides massive computational boost to biomedical research at TGen
In less time than the blink of an eye, the Translational Genomics Research Institute's new supercomputer at Arizona State University can do operations equal to every dollar in the recent Wall Street bailout.
Prostate cancer gene test provides new early detection
Prostate cancer (PCa) is one of the most common male cancers in the Western world. Currently, early detection of PCa depends on an abnormal digital rectal examination and an elevated prostate-specific-antigen (PSA) level requiring a prostate biopsy, often associated with anxiety, discomfort, complications, and heavy expenses.
New Catheter-less Technique May Ease the Pain and Discomfort of Prostate Cancer Recovery
To ease the pain of recovery following prostate cancer surgery, physician-scientists have developed an innovative and patient-friendly approach that eliminates the use of a penile urinary catheter.
Racial disparities decline for cancer in Missouri
Cancer death rates in the United States are highest among African Americans, but a new report shows that in Missouri the disparity in cancer incidence and death between African Americans and whites is declining.
OHSU Cancer Institute researchers study breathing during radiation
Oregon Health & Science University researchers have determined exactly how much breathing affects prostate movement during radiation treatment.
Hormone therapy before radiation seed implants for prostate cancer
Men over 70 years of age with early-stage prostate cancer have 20 percent higher mortality if they are treated first with hormone therapy before being treated with radiation seed implants (brachytherapy), compared to men who are treated with brachytherapy alone.
Newly found gene variants account for kidney diseases among African-Americans
For the first time, researchers have identified variations in a single gene that are strongly associated with kidney diseases disproportionately affecting African-Americans. This work was conducted by researchers at the National Institutes of Health (NIH) and by NIH-funded investigators at the Johns Hopkins University.
More Prostate Cancer Current Events and Prostate Cancer News Articles
 | Dr. Patrick Walsh's Guide to Surviving Prostate Cancer, Second Edition by Patrick C. Walsh, Janet Farrar Worthington EVERY MAN NEEDS THIS BOOK! Each year, more than 200,00 American men are diagnosed with prostate cancer. The good news is that more men are being cured of this disease than ever before. Now in a revised second edition, this lifesaving guide by Dr. Patrick Walsh and ard-winning science writer Janet Farrar Worthington offers a message of hope to every man facing this illness. Prostate cancer is... |
 | A Primer on Prostate Cancer: The Empowered Patient's Guide by Stephen Strum, Donna L. Pogliano ¡§A Primer on Prostate Cancer, The Empowered Patient¡¦s Guide¡¨ is a basic resource to be used by patients and physicians when there has been a diagnosis of prostate cancer. It outlines a strategy of disease management that is designed to maximize outcomes for the patient and his loved ones. All aspects of diagnosis and testing are discussed; all currently approved treatments for prostate... |
 | Eat to Beat Prostate Cancer Cookbook by David Ricketts Prostate cancer is now the most common nonskin cancer among men in the United States. In 2005 alone, 250,000 new cases were diagnosed, and that number is certain to rise with each passing year. No one is more aware of this than David Ricketts, experienced cookbook author and recent prostate cancer survivor.Shortly after surgery and radiation treatments, Ricketts began to research food and... |
 | Surviving Prostate Cancer Without Surgery by Bradley Hennenfent The niche bestseller "Surviving Prostate Cancer Without Surgery" begins with the shooting of a urologist and includes a World War II Battle. The book exposes the big lie about radical prostate surgery, is filled with cartoons and simple diagrams, and is written for the average layperson in easy-to-understand style. "Surviving Prostate Cancer Without Surgery" quotes Dr. Gary Onik, M.D.,... |
 | You Can Beat Prostate Cancer by Robert J. Marckini The task of choosing the right prostate cancer treatment is daunting. It is further complicated by conflicting information the patient receives from physicians and the Internet. This book is written by a prostate cancer survivor who now runs an international prostate cancer support group. It's about his journey and the important things he learned along the way. It is the book the author wishes... |
 | The Prostate Cancer Treatment Book by Peter Grimm, John Blasko, John Sylvester The latest and most progressive treatment advice from prostate cancer experts at the nation's top medical centers For each of the nearly 200,000 Americans diagnosed with prostate cancer annually, the months following the diagnosis are a time of momentous decisions and enormous emotional strain. This book offers readers complete answers to all their questions about the best treatment options for... |
 | Prostate And Cancer: A Family Guide To Diagnosis, Treatment And Survival (3rd Edition) by Sheldon Marks Prostate cancer has become the most-diagnosed cancer in America and the second leading killer of men. Sadly, more than 189,000 men will be diagnosed with the disease in 2002. Dr. Sheldon Marks, a specialist in the diagnosis and treatment of prostate cancer, is the authority that many have come to depend on-both in his practice and through his book, Prostate and Cancer-when cancer has posed a... |
 | Surviving Prostate Cancer without Surgery: The New Gold Standard Treatment That Can Save Your Life and Lifestyle by Michael J. Dattoli, Jennifer Cash, Don Kaltenbach Unlike any other book on the subject, Surviving Prostate Cancer Without Surgery provides the most up-to-date information and lifesaving advice from three essential points of view -- physician, nurse, and patient-survivor. Three leading cancer care specialists guide readers step by step through diagnosis, treatment and recovery, covering both the physical and emotional challenges of the disease. ... |
 | Surviving Prostate Cancer: What You Need to Know to Make Informed Decisions (Yale University Press Health & Wellness) by E. Fuller Torrey When Dr. E. Fuller Torrey was diagnosed with prostate cancer, none of the books he could find was current enough or comprehensive enough to satisfy his need for information. This book is for the hundreds of thousands of other men who each year receive the same frightening diagnosis. It is the book Dr. Torrey wished he had when he was facing the countless questions that a man with prostate cancer,... |
 | PROSTATE CANCER MEETS THE PROTON BEAM: A Patient's Experience by Fuller Jones Proton Beam Therapy is an advanced cancer treatment based on the elegant physics of the proton. It is not well known, because there are currently only five hospitals in the U.S. that have the expensive and complex equipment to administer it. Protons have been used for cancer treatment in the U. S. since 1990 with success comparable to all other options, but with minimal side effects. Proton... |
| © 2008 BrightSurf.com |